```
==============================================================
```
Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2010; month=7; day=21; hr=6; min=38; sec=33; ms=951;]
```
==============================================================
```

Application No: 10559758   Version No: 4.0

Input Set:

Output Set:

Started: 2010-07-20 11:54:45.552
Finished: 2010-07-20 11:54:48.742
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 190 ms
Total Warnings: 62
Total Errors: 0
No. of SeqIDs Defined: 62
Actual SeqID Count: 62

Error code   Error Description

W   213   Artificial or Unknown found in <213> in SEQ ID (1)

W   213   Artificial or Unknown found in <213> in SEQ ID (2)

W   213   Artificial or Unknown found in <213> in SEQ ID (3)

W   213   Artificial or Unknown found in <213> in SEQ ID (4)

W   213   Artificial or Unknown found in <213> in SEQ ID (5)

W   213   Artificial or Unknown found in <213> in SEQ ID (6)

W   213   Artificial or Unknown found in <213> in SEQ ID (7)

W   213   Artificial or Unknown found in <213> in SEQ ID (8)

W   213   Artificial or Unknown found in <213> in SEQ ID (9)

W   213   Artificial or Unknown found in <213> in SEQ ID (10)

W   213   Artificial or Unknown found in <213> in SEQ ID (11)

W   213   Artificial or Unknown found in <213> in SEQ ID (12)

W   213   Artificial or Unknown found in <213> in SEQ ID (13)

W   213   Artificial or Unknown found in <213> in SEQ ID (14)

W   213   Artificial or Unknown found in <213> in SEQ ID (15)

W   213   Artificial or Unknown found in <213> in SEQ ID (16)

W   213   Artificial or Unknown found in <213> in SEQ ID (17)

W   213   Artificial or Unknown found in <213> in SEQ ID (18)

W   213   Artificial or Unknown found in <213> in SEQ ID (19)

W   213   Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started:	2010-07-20 11:54:45.552
Finished:	2010-07-20 11:54:48.742
Elapsed:	0 hr(s) 0 min(s) 3 sec(s) 190 ms
Total Warnings:	62
Total Errors:	0
No. of SeqIDs Defined:	62
Actual SeqID Count:	62

Error code	Error Description
	This error has occured more than 20 times, will not be displayed

<110> Hart, Stephen Lewis
       Writer, Michele

<120> PEPTIDE LIGANDS

<130> ABL-012.1P US

<140> 10559758
<141> 2010-07-20

<150> GB 03 13132.3
<151> 2003-06-06

<150> PCT/GB2004/002421
<151> 2004-06-07

<160> 62

<170> PatentIn version 3.5

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
       ny amino acid residue, Xaa at position 4 = any amino acid residue

<400> 1

Pro Xaa Xaa Xaa Thr
1   5

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa at position 3 = any amino acid residue

<400> 2

Pro Ser Xaa Ser
1

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid, Xaa at position 3 = any amino
      acid having an amide side chain, Xaa at position 4 = any amino a
      cid

<400> 3

Gln Xaa Xaa Xaa Gln
1   5

<210> 4
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue having an aliphatic si
      de chain

<400> 4

Ser Xaa Ser
1

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 5

Pro Xaa Leu Xaa Thr
1   5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 6

Pro Ala Leu Lys Thr
1   5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr
1   5

```
<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells

<400>  8

Pro Ser Asn Ser Thr
1               5


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells

<400>  9

Pro Pro Asn Thr Thr
1               5


<210>  10
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (2)..(4)
<223>  Xaa at position 2 = any amino acid residue, Xaa at position 3 =
       an y amino acid residue, Xaa at position 4 = any amino acid
       residue

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 = any amino acid resdue

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 = any amino acid residue

<400>  10

Pro Xaa Xaa Xaa Thr Xaa
```

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid residue

<400> 11

Pro Xaa Leu Xaa Thr Xaa
1   5

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid residue

```
<400>  12

Pro Xaa Asn Xaa Thr Xaa
1               5


<210>  13
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 = any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (3)..(5)
<223>  Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
       ny amino acid residue, Xaa at position 5 = any amino acid residue

<400>  13

Xaa Pro Xaa Xaa Xaa Thr
1               5


<210>  14
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 = any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (3)..(5)
<223>  Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
       ny amino acid residue, Xaa at position 5 = any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 = any amino acid residue
```

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa
1   5

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 15

Ala Pro Ser Asn Ser Thr Ala
1   5

<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 16

Ser Pro Ala Leu Lys Thr Val
1   5

<210> 17
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 17

Ser Thr Pro Pro Asn Thr Thr
1   5

<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 18

Pro Ser Asn Ser
1

<210> 19
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 19

Pro Ser Leu Ser
1

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 = Ala or Lys

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser
1   5

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 21

Ala Pro Ser Asn Ser
1   5

<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 22

Leu Pro Ser Leu Ser
1   5

<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 23

Met Leu Pro Ser Leu Ser
1   5

<210> 24
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 24

Pro Met Leu Pro Ser Leu Ser
1   5

<210> 25
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 25

Ser Gln Lys Asn Pro Gln Met
1   5

```
<210>   26
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   26

Phe Gln Ser Gln Tyr Gln Lys
1               5


<210>   27
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   27

Met Ala Ser Ile Ser Met Lys
1               5


<210>   28
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   28

Asp Trp Trp His Thr Ser Ala
1               5


<210>   29
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   29

Ser His Val Lys Leu Asn Ser
1               5


<210>   30
```

```
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   30

Gln Leu Leu Thr Gly Ala Ser
1               5


<210>   31
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   31

Thr Ala Arg Asp Tyr Arg Leu
1               5


<210>   32
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   32

Phe Pro Arg Ala Pro His His
1               5


<210>   33
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide binding to dendritic cells

<400>   33

Ser Glu Trp Leu Ser Ala Leu
1               5


<210>   34
<211>   7
```

<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 34

Ile Gly Gly Ile Arg Arg His
1   5

<210> 35
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 35

Tyr Thr Met Glu Phe Asn Arg
1   5

<210> 36
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 36

Pro Ala Ala Tyr Lys Ala His
1   5

<210> 37
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
      ny amino acid residue, Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE

```
<222>  (6)..(6)
<223>  Xaa at position 6 = Ala or Val


<400>  37

Pro Xaa Xaa Xaa Thr Xaa
1                   5



<210>  38
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa at position 2 = any amino acid residue,

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 = any amino acid residue,

<400>  38

Pro Xaa Asn Xaa Thr
1                   5



<210>  39
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (2)..(4)
<223>  Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
       sn or Leu, Xaa at position 4 = any amino acid residue

<400>  39

Pro Xaa Xaa Xaa Thr
1                   5



<210>  40
<211>  5
```

```
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa at position 2 = any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position  = Thr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position  4 = Thr or Ser

<400>  40

Pro Xaa Asn Xaa Thr
1               5


<210>  41
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide binding to dendritic cells


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 = Ala or Leu

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 = any amino acid residue

<400>  41

Xaa Pro Ser Xaa Ser
1               5


<210>  42
<211>  5
<212>  PRT
<213>  Artificial Sequence
```

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
       sn or Gln, Xaa at position 3 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 =
       Asn or Gln, Xaa at position 4 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln
1   5

<210> 43
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = Leu or Ile

<400> 43

Ser Xaa Ser
1

<210> 44
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Ser His Val Lys Leu Asn Ser Cys Gly
            20   25

<210>   45
<211>   28
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Peptide derivative of the invention

<400>   45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly
            20   25

<210>   46
<211>   28
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Peptide derivative of the invention

<400>   46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly
            20   25

<210>   47
<211>   28
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Peptide derivative of the invention

<400>   47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly
            20   25

<210> 48
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly
            20   25

<210> 49
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly
            20   25

<210> 50
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly
            20   25

<210> 51
<211> 27

<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 51

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Arg Arg Glu Glu Trp Ala Cys Gly
            20   25

<210> 52
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 52

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gln
            20   25

<210> 53
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> integrin-binding peptide

<400> 53

Arg Arg Glu Thr Glu Trp Ala
1   5

<210> 54
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic nucleic acid binding domain

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

<210> 55
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> hydrophobic spacer sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> x = epsilon-amino hexanoic acid residue

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> x = epsilon-amino hexanoic acid residue

<400> 55

Xaa Ser Xaa Gly Ala
1   5

<210> 56
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 56
ccctcattag cgtaacg   17

<210> 57
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> control peptide

<400> 57

Ala Thr Arg Trp Ala Arg Glu
1   5

<210> 58

<211>   24
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Oligonucleotide encoding peptide ligand

<400>   58
ccggaagcca cgtcaagctg aacg